Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > REGULATORY
REGULATORY
- Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
September 22, 2023
- Chuikyo Rep Grumbles at Too Many Industry Requests, FPMAJ Chief Wants Health Coverage Dabate
September 21, 2023
- Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Launches Fall COVID-19 Vaccination Campaign
September 21, 2023
- Apply Brand-Based Price Revisions to Qualified Generic Makers: JGA
September 21, 2023
- JPWA Urges Price Hikes for Drugs with NHI Tag Below 20 Yen
September 21, 2023
- MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
- 10-20% of Infected Adults Suffer Long COVID: MHLW Study
September 20, 2023
- Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
September 20, 2023
- Hamachi, Miyazaki Named Senior Vice Health Ministers
September 19, 2023
- Health Minister Set to Visit Boston Life Sciences Cluster
September 19, 2023
- Opposition Party Leader Raps Takemi’s Appointment as Health Minister
September 19, 2023
- Japan Grants Orphan Tag to Tafinlar/Mekinist, Retevmo
September 19, 2023
- Japan to Require Out-of-Pocket Cost for COVID Drugs from October
September 19, 2023
- New Health Minister Vows to Put Public Needs First in 2024 Drug Pricing Reform
September 15, 2023
- Japan to Basically Drop Japanese PI Requirement before Global Clinical Trials
September 14, 2023
- Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
September 14, 2023
- Bimzelx, Pivlaz Escape Price Cuts after Cost-Effectiveness Assessments
September 14, 2023
- Keizo Takemi Tapped as New Health Minister in Cabinet Reshuffle
September 14, 2023
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…